Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06306443 · ClinicalTrials.gov registry record · Phase 3
Buprenorphine for Individuals in Jail
A Phase 3 study of Opioid Use Disorder, sponsored by Friends Research Institute.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 240
- Enrollment target
- 2
- Study locations
NCT06306443: Recruiting Phase 3 study of Opioid Use Disorder, sponsored by Friends Research Institute.
NCT06306443 is a Phase 3 study of Opioid Use Disorder that is actively recruiting participants, run by Friends Research Institute. The registered enrollment target is 240 participants, below the 4,655-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (95% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06306443, a Phase 3 study of Opioid Use Disorder, is actively recruiting participants, sponsored by Friends Research Institute.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 240 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study is an open label randomized controlled trial of extended-release buprenorphine (BRIXADI, XR-B) vs. sublingual buprenorphine (SL-B) in a large metropolitan jail. An open-label design will randomly assign 240 adults with moderate-to-severe OUDs who are soon-to-be-released from jail to either XR-B (n=120) or SL-B (n=120) treatment in jail followed by 6-months of post-release buprenorphine treatment, a 7-month safety visit, and a final long-term follow-up at 12-months.
Primary Outcome
positive urine drug screen for opioids
Conditions Studied
Interventions
- DRUG extended-release buprenorphine (XR-B)
Study Locations (2)
Maryland
- Friends Research Institute - Baltimore
- Baltimore Central Booking & Intake Center - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2025-07-01 |
| Est. Completion | 2029-12-31 |
| Phase | Phase 3 |
What NCT06306443 shows while recruiting
NCT06306443 is an interventional study that assigns participants to a tested intervention. The registered 240 participants enrollment target is mid-sized for trials with a published cap, below the 4,655-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Opioid Use Disorder appearing as the primary indexed condition, and to 1 intervention - of which extended-release buprenorphine (XR-B) is the first listed.
NCT06306443 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT06306443 about?
NCT06306443 is a clinical study titled "Buprenorphine for Individuals in Jail". This study is an open label randomized controlled trial of extended-release buprenorphine (BRIXADI, XR-B) vs. sublingual buprenorphine (SL-B) in a large metropolitan jail. An open-label design will randomly assign 240 adults with moderate-to-severe OUDs who are soon-to-be-released from jail to eithe...
What is the current status of trial NCT06306443?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 240 participants. The study started on 2025-07-01. Estimated completion is 2029-12-31.
What conditions does trial NCT06306443 study?
This clinical trial studies the following conditions: Opioid Use Disorder.
What interventions are being tested in trial NCT06306443?
The interventions under investigation include: extended-release buprenorphine (XR-B) (DRUG).
Who is sponsoring clinical trial NCT06306443?
This trial is sponsored by Friends Research Institute, which has 41 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06306443 being conducted?
This trial has 2 study locations across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Opioid Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06306443's enrollment target sits among peer trials
240 75th of 257 higher than 180 of 257 other Opioid Use Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Opioid Use Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Standard Versus High Dose ED-Initiated Buprenorphine Induction
RECRUITING · Phase 3
-
Treating Polysubstance Use Using a Novel Digital Technology
RECRUITING · Phase 3
-
High Dose Buprenorphine (BUP) Induction in the Emergency Department (ED)
RECRUITING · Phase 3
-
Non-invasive Vagal Nerve Stimulation in Opioid Use Disorders UH3
RECRUITING · Phase 3
-
Transdermal Patch for BupRenorphine Induction DurinG PrEgnancy (Patch BRIDGE)
RECRUITING · Phase 3
-
Behavioral Pharmacological Examination of a Novel Buprenorphine Induction Method Among Individuals Who Use Fentanyl
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02855554 · 240 participants · NA
Quantitative Cardiac Parametric Mapping
- NCT03230565 · 240 participants · Phase 4
Continuous Infusions vs Scheduled Bolus Infusions
- NCT03399929 · 240 participants
Traumatic Brain Injury and Stroke Long Term Outcome
- NCT03583710 · 240 participants · Phase 3
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI